Immune system and tumor microenvironment in early-stage breast cancer: different mechanisms for early recurrence after mastectomy and chemotherapy on ductal and lobular types

Background: The most common type of breast cancer is the ductal type (IDC), followed by lobular type (ILC). Surgery is the main therapy for early-stage breast cancer. Adjuvant chemotherapy might be given to those at high risk of recurrence. Recurrence is still possible after mastectomy and chemotherapy and most often occurs in the first two years. We aimed to determine the mechanisms in early local recurrence in both types. Methods: We used an observational method with a cross-sectional study design. The samples were patients with early-stage IDC and ILC, who underwent modified radical mastectomy (MRM) and got adjuvant chemotherapy with taxan and anthracycline base, and experienced recurrence in the first two years after surgery. The materials in this study were paraffin blocks from surgical specimens; we examined vimentin, α-SMA and MMP1, PDGF and CD95 by immunohistochemistry (IHC). Data analysis was done using OpenEpi 3.0.1 and EZR. We used pathway analysis with linear regression. Results: There were 25 samples with local recurrence and 25 samples without recurrence in the ductal type group. The lobular type group consisted of six subjects without recurrence and seven with recurrence. There were significant differences in the expression of vimentin (p = 0.000 and 0.021, respectively), PDGF (p = 0.000 and 0.002) and CD95 (p = 0.000 and 0.045) in ductal and lobular cancer types, respectively. MMP1 (p = 0.000) and α-SMA (p = 0.000) only showed a significant difference in the ductal type. The pathway analysis showed that in the ductal type, the mechanism of recurrence was enabled by two factors: α-SMA and CD95. Meanwhile, for the lobular type, the recurrence mechanism was through the CD95 pathway. Conclusions: Local recurrence in early-stage IDC and ILC had different mechanisms.  These findings are expected to make cancer treatment in both types more focused and efficient.

[1]  Mengxuan Zhu,et al.  The STAT family: key transcription factors mediating crosstalk between cancer stem cells and tumor immune microenvironment. , 2022, Seminars in cancer biology.

[2]  A. Brohl,et al.  Classical epithelial-mesenchymal transition (EMT) and alternative cell death process-driven blebbishield metastatic-witch (BMW) pathways to cancer metastasis , 2022, Signal Transduction and Targeted Therapy.

[3]  Gaurav Sharma,et al.  Triple-negative breast cancer metastasis involves complex epithelial-mesenchymal transition dynamics and requires vimentin , 2022, Science Translational Medicine.

[4]  Xixi Lin,et al.  Cancer‐associated fibroblasts in breast cancer: Challenges and opportunities , 2022, Cancer communications.

[5]  J. Eriksson,et al.  Roles of vimentin in health and disease , 2022, Genes & development.

[6]  Xin Lu,et al.  Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer , 2022, Cancers.

[7]  O. Agbulut,et al.  Vimentin: Regulation and pathogenesis. , 2022, Biochimie.

[8]  M. Kerin,et al.  Differences in sensitivity to neoadjuvant chemotherapy among invasive lobular and ductal carcinoma of the breast and implications on surgery–A systematic review and meta-analysis , 2021, The Breast : Official Journal of the European Society of Mastology.

[9]  Suhair Hikmat,et al.  PI3K/AKT and MAPK1 molecular changes preceding matrix metallopeptidases overexpression during tamoxifen-resistance development are correlated to poor prognosis in breast cancer patients , 2021, Breast Cancer.

[10]  G. Tse,et al.  Tumor Microenvironment in Breast Cancer—Updates on Therapeutic Implications and Pathologic Assessment , 2021, Cancers.

[11]  P. Angrand,et al.  Vimentin Promotes the Aggressiveness of Triple Negative Breast Cancer Cells Surviving Chemotherapeutic Treatment , 2021, Cells.

[12]  A. Musolino,et al.  Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression , 2021, Molecular Diagnosis & Therapy.

[13]  Chien-Yu Huang,et al.  Identified the novel resistant biomarkers for taxane-based therapy for triple-negative breast cancer , 2021, International journal of medical sciences.

[14]  G. Cakmak,et al.  A Comparison Between Modified Radical Mastectomy and Breast-Conserving Surgery Concerning the Quality of Life in Patients with Breast Cancer Under 50 Years of Age , 2021 .

[15]  Seyeon Park,et al.  Comparison of PECS II and erector spinae plane block for postoperative analgesia following modified radical mastectomy: Bayesian network meta-analysis using a control group , 2021, Journal of Anesthesia.

[16]  J. Lee,et al.  Inhibition of platelet-derived growth factor receptor synergistically increases the pharmacological effect of tamoxifen in estrogen receptor α positive breast cancer , 2021, Oncology letters.

[17]  N. Wilson,et al.  Lobular Breast Cancer: A Review , 2021, Frontiers in Oncology.

[18]  Tyler T. Risom,et al.  Transition to invasive breast cancer is associated with progressive changes in the structure and composition of tumor stroma , 2021, Cell.

[19]  Zhengxu Fang,et al.  Regulatory mechanisms and clinical significance of vimentin in breast cancer. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  S. Oesterreich,et al.  Estrogen Regulation of mTOR Signaling and Mitochondrial Function in Invasive Lobular Carcinoma Cell Lines Requires WNT4 , 2020, Cancers.

[21]  A. Vincent-Salomon,et al.  A subset of activated fibroblasts is associated with distant relapse in early luminal breast cancer , 2020, Breast Cancer Research.

[22]  Fang Yan,et al.  Vimentin plays an important role in the promotion of breast cancer cell migration and invasion by leucine aminopeptidase 3 , 2020, Cytotechnology.

[23]  M. Barry,et al.  Health-related quality of life following breast reconstruction compared to total mastectomy and breast-conserving surgery among breast cancer survivors: a systematic review and meta-analysis , 2020, Breast Cancer.

[24]  Zhi-wen Li,et al.  Radiotherapy after mastectomy has significant survival benefits for inflammatory breast cancer: a SEER population-based retrospective study , 2020, PeerJ.

[25]  Patrick Legembre,et al.  CD95/Fas and metastatic disease: What does not kill you makes you stronger. , 2020, Seminars in cancer biology.

[26]  M. Peter,et al.  The mechanism of how CD95/Fas activates the Type I IFN/STAT1 axis, driving cancer stemness in breast cancer , 2020, Scientific Reports.

[27]  S. Grobmyer,et al.  Management Strategies for Locally Recurrent Breast Cancer: Redo-Lumpectomy, Redo-Sentinel Node Biopsy, Redo-Radiation , 2019, Annals of Surgical Oncology.

[28]  Rosana Pelayo,et al.  Breast Cancer Subtypes Present a Differential Production of Reactive Oxygen Species (ROS) and Susceptibility to Antioxidant Treatment , 2019, Front. Oncol..

[29]  G. Stassi,et al.  Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance , 2019, Molecular Cancer.

[30]  S. Yoo,et al.  Recent Advances in Cancer Stem Cell-Targeted Immunotherapy , 2019, Cancers.

[31]  Lihong Shi,et al.  Leucine aminopeptidase 3 promotes migration and invasion of breast cancer cells through upregulation of fascin and matrix metalloproteinases‐2/9 expression , 2018, Journal of cellular biochemistry.

[32]  O. Olopade,et al.  HIF-2α promotes conversion to a stem cell phenotype and induces chemoresistance in breast cancer cells by activating Wnt and Notch pathways , 2018, Journal of Experimental & Clinical Cancer Research.

[33]  Lili Wang,et al.  Activation of STAT3 and Bcl-2 and reduction of reactive oxygen species (ROS) promote radioresistance in breast cancer and overcome of radioresistance with niclosamide , 2018, Oncogene.

[34]  Inna Kuperstein,et al.  Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer. , 2018, Cancer cell.

[35]  K. Pietras,et al.  The PDGF pathway in breast cancer is linked to tumour aggressiveness, triple-negative subtype and early recurrence , 2018, Breast Cancer Research and Treatment.

[36]  A. Kappo,et al.  Roles of Heat Shock Proteins in Apoptosis, Oxidative Stress, Human Inflammatory Diseases, and Cancer , 2017, Pharmaceuticals.

[37]  Min Yi,et al.  Invasive lobular carcinoma of the breast: A special histological type compared with invasive ductal carcinoma , 2017, PloS one.

[38]  Y. Cheng,et al.  MMP1 expression is activated by Slug and enhances multi-drug resistance (MDR) in breast cancer , 2017, PloS one.

[39]  M. Sang,et al.  Biomarkers for EMT and MET in breast cancer: An update. , 2016, Oncology letters.

[40]  Xiaobing Shi,et al.  LSD1 binds to HPV16 E7 and promotes the epithelial-mesenchymal transition in cervical cancer by demethylating histones at the Vimentin promoter , 2016, Oncotarget.

[41]  G. Christofori,et al.  The relevance of EMT in breast cancer metastasis: Correlation or causality? , 2015, FEBS letters.

[42]  K. Oda,et al.  Matrix Metalloproteinase (MMP)-9 in Cancer-Associated Fibroblasts (CAFs) Is Suppressed by Omega-3 Polyunsaturated Fatty Acids In Vitro and In Vivo , 2014, PloS one.

[43]  A. Kallioniemi,et al.  The impact of lobular and ductal breast cancer histology on the metastatic behavior and long term survival of breast cancer patients. , 2013, Breast.

[44]  M. Reeves,et al.  Rate of Re-excision after Breast-conserving Surgery for Invasive Lobular Carcinoma , 2013, The American surgeon.

[45]  E. Tokunaga,et al.  Vimentin as a poor prognostic factor for triple-negative breast cancer , 2013, Journal of Cancer Research and Clinical Oncology.

[46]  H. Moch,et al.  Re-excision Rates and Local Recurrence in Breast Cancer Patients Undergoing Breast Conserving Therapy , 2012, Senologie.

[47]  D. Radisky,et al.  Matrix Metalloproteinase Induction of Rac1b, a Key Effector of Lung Cancer Progression , 2012, Science Translational Medicine.

[48]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[49]  S. Agelaki,et al.  Epithelial to mesenchymal transition markers expressed in circulating tumour cells of early and metastatic breast cancer patients , 2011, Breast Cancer Research.

[50]  Karen Gelmon,et al.  Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  M. García,et al.  Expression of metalloproteases and their inhibitors in different histological types of breast cancer , 2010, Journal of Cancer Research and Clinical Oncology.

[52]  F. Nakamura,et al.  Filamin A is required for vimentin-mediated cell adhesion and spreading. , 2010, American journal of physiology. Cell physiology.

[53]  M. Sogayar,et al.  Correlation between MMPs and their inhibitors in breast cancer tumor tissue specimens and in cell lines with different metastatic potential , 2009, BMC Cancer.

[54]  S. Shukla,et al.  Cytokeratin and Vimentin Expression in Breast Cancer , 2009 .

[55]  Boguslaw Stec,et al.  The Fas/FADD death domain complex structure unravels signaling by receptor clustering , 2008, Nature.

[56]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[57]  J. Gregg,et al.  EMT tumorigenesis in the mouse mammary gland , 2007, Laboratory Investigation.

[58]  J. Benítez,et al.  Vimentin and laminin expression is associated with basal-like phenotype in both sporadic and BRCA1-associated breast carcinomas , 2006, Journal of Clinical Pathology.

[59]  J. Forbes,et al.  Risk factors for locoregional recurrence among breast cancer patients: results from International Breast Cancer Study Group Trials I through VII. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[60]  Z. Werb,et al.  New functions for the matrix metalloproteinases in cancer progression , 2002, Nature Reviews Cancer.

[61]  M. Beckmann,et al.  CD95 ligand expression as a mechanism of immune escape in breast cancer , 2000, Immunology.

[62]  U. Hellman,et al.  PDGF induces reorganization of vimentin filaments. , 1998, Journal of cell science.

[63]  D. Horsfall,et al.  Vimentin expression is not associated with poor prognosis in breast cancer , 1996, International journal of cancer.

[64]  Jean Paul Thiery,et al.  Expression of smooth muscle-specific proteins in myoepithelium and stromal myofibroblasts of normal and malignant human breast tissue. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[65]  Huan Li,et al.  Effect of modified radical mastectomy combined with neo-adjuvant chemotherapy on postoperative recurrence rate, negative emotion, and life quality of patients with breast cancer. , 2022, American journal of translational research.

[66]  M. Sangen.  Locoregional control of breast cancer with an emphasis on the role of young age and lobular histology , 2013 .

[67]  I. Witz,et al.  The Tumor Microenvironment , 2012 .